Zobrazeno 1 - 10
of 356
pro vyhledávání: '"Seruga B"'
Publikováno v:
In ESMO Open March 2024 9(3)
Autor:
Seruga, B. ∗, Sullivan, R. †, ‡, Fundytus, A. §, Hopman, W.M. §, ||, Ocana, A. ¶, ∗∗, Joffe, J. ††, Bodoky, G. ‡‡, Le Tourneau, C. §§, Vanderpuye, V. ||||, Lopes, G. ¶¶, Hammad, N. ∗∗∗, Sengar, M. †††, Brundage, M.D. §, ∗∗∗, Booth, C.M. §, ||, ∗∗∗
Publikováno v:
In Clinical Oncology January 2020 32(1):e19-e26
Publikováno v:
In Clinical Oncology April 2018 30(4):215-224
Publikováno v:
In ESMO Open February 2024 9 Supplement 1
Autor:
AlHashem, H.Y. ∗, †, ‡, Al-Mubarak, M. ∗, †, Vera-Badillo, F.E. ∗, †, Templeton, A.J. ∗, †, Ocana, A. §, Seruga, B. ¶, Amir, E. ∗, †, ∗
Publikováno v:
In Clinical Oncology May 2016 28(5):283-291
Autor:
Srikanthan, A., Vera-Badillo, F., Ethier, J., Goldstein, R., Templeton, A.J., Ocana, A., Seruga, B., Amir, E.
Publikováno v:
In Cancer Treatment Reviews February 2016 43:67-73
Publikováno v:
In Annals of Oncology November 2012 23(11):2977-2982
Publikováno v:
In Annals of Oncology August 2012 23(8):2161-2166
Autor:
Kovac Milena Blaz, Seruga Bostjan
Publikováno v:
Radiology and Oncology, Vol 58, Iss 2, Pp 170-178 (2024)
Various types of immunotherapy (i.e. immune checkpoint inhibitors [ICIs], chimeric antigen receptor [CAR] T-cells and bispecific T-cell engagers [BiTEs]) and antibody drug conjugates (ADCs) have been used increasingly to treat solid cancers, lymphoma
Externí odkaz:
https://doaj.org/article/b1cc3e3d0d114890aa3c517c510bd9fe
Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer
Autor:
Seruga, B., Hertz, P.C., Wang, L., Booth, C.M., Cescon, D.W., Krzyzanowska, M., Tannock, I.F. *
Publikováno v:
In Annals of Oncology July 2010 21(7):1411-1418